A trial looking at the monoclonal antibody Chi Lob 7/4 for advanced cancer

Cancer type:

All cancer types




Phase 1

This trial looked at treating advanced cancer with a monoclonal antibody called Chi Lob 7/4. This trial was supported by Cancer Research UK.

More about this trial

Most cancers are treated with standard treatments such as surgery, chemotherapy, radiotherapy or hormone therapy. But sometimes cancer comes back after initial treatment. If that happens the cancer is more difficult to treat.

CD40 is a protein (antigen) found on the surface of some cancer cells and some cells in the immune system. Chi Lob 7/4 is a monoclonal antibody which works in 2 different ways.

  • It targets cancer cells with CD40 antigen on their surface and this may lead to the cancer cells being killed.
  • It may help normal immune system cells to recognise and kill cancer cells.

Doctors hoped that this new drug would be useful for treating advanced cancer that is no longer responding to standard treatment.

Research carried out in laboratories has shown that the Chi Lob 7/4 monoclonal antibody targets and kills cancer cells. But this was the first time that it was tested in patients.

The aims of the trial were to find out

  • The best dose of Chi Lob 7/4 to give
  • What the side effects are
  • How well it works
  • What happens to Chi Lob 7/4 in your body
  • How quickly your body gets rid of it

Summary of results

From this phase 1 clinical trial, doctors found that Chi Lob 7/4 was safe to give. Everybody in the trial had advanced cancer Open a glossary item. No one who had Chi Lob 7/4 had an improvement in their cancer, but some people’s cancer stayed the same and didn’t get any worse.

The doctors aimed to give Chi Lob 7/4 through a drip into a vein once a week for up to 4 weeks. The first 3 patients had the lowest dose of Chi Lob 7/4. The next 3 patients had a higher dose. And so on, until the doctors found the best dose of Chi Lob 7/4 to give.

In total 28 people had Chi Lob 7/4 and 25 people had treatment over 4 weeks. The best dose given (the maximum tolerated dose) was 200mg.

The most common side effects which the doctors thought were probably related to having Chi Lob 7/4 were

  • A reaction to having the drug causing shivering, low blood pressure and a high temperature (fever)
  • Headache
  • Tiredness
  • Diarrhoea

Because of the possibility of having a reaction to the drug, people given higher doses than 50 mg had steroids, an anti-allergy drug and paracetamol to control a high temperature before the Chi Lob 7/4.

The doctors looked at how the drug works in the body. They found that

  • In 7 people there was a reaction which could mean that the immune system was activated but this response was not seen in people who had more than 50mg of the drug
  • There was a fall in the numbers of certain cells that are an important part of the immune system, B cells and NK (natural killer) cells
  • There were increases in the levels of some proteins which encourage the body to make other types of immune cells such as IL-12 and IL-6
  • The level of the drug in the blood peaked in the first 3 hours after it was given. There was no evidence of the drug in the blood of anyone who had it 8 weeks after it was given.

15 people’s cancer remained the same (stable disease) after 8 weeks of the trial.

In conclusion Chi Lob 7/4 is a safe drug and it did activate the immune system but in this trial it did not improve the cancer of anyone who took part. The researchers think that in the future it should be tested in combination with chemotherapy or another type of monoclonal antibody.

We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor P Johnson

Supported by

Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)

Other information

This is Cancer Research UK trial number CRUKD/07/063.

We have more information about the work of Professor Peter Johnson.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 673

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page